Medicure Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Medicure heeft een totaal eigen vermogen van CA$20.0M en een totale schuld van CA$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk CA$28.5M en CA$8.5M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

CA$0

Schuld

Rente dekkingsratio	n/a
Contant	CA$4.90m
Aandelen	CA$19.98m
Totaal verplichtingen	CA$8.51m
Totaal activa	CA$28.50m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely

Jun 15

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$16.2M ) MPH } overtreffen de korte termijn passiva ( CA$8.0M ).

Langlopende schulden: De kortetermijnactiva MPH ( CA$16.2M ) overtreffen de langetermijnschulden ( CA$556.0K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: MPH is schuldenvrij.

Schuld verminderen: MPH had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Er zijn onvoldoende gegevens om te bepalen of MPH voldoende cash runway heeft op basis van de huidige vrije kasstroom.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of MPH voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Medicure Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Third quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 3Q 2023)

Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of Directors

Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024

Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)

Medicure Inc.'s (CVE:MPH) Price Is Right But Growth Is Lacking

Now 35% undervalued after recent price drop

Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director

First quarter 2024 earnings released

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Medicure Inc. (CVE:MPH)

Medicure Inc., Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)

Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024

Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel

New major risk - Share price stability

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 24%

Investor sentiment deteriorates as stock falls 17%

Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022)

New minor risk - Profit margin trend

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease

Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022)

Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 16%

First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022)

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021)

Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors

Investor sentiment improved over the past week

Founder recently bought CA$67k worth of stock

Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem

Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021)

Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022

Insufficient new directors

Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021)

Investor sentiment improved over the past week

Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022

Investor sentiment improved over the past week

Medicure Inc. Appoints James Kinley as Director

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Medicure Inc., Annual General Meeting, Jun 16, 2022

Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of Americans

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020)

Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely

CFO & Secretary has left the company

First quarter 2021 earnings released

Full year 2020 earnings released

New 90-day high: CA$1.70

Medicure Announces Early Completion of Enrollment for iSPASM

New 90-day high: CA$1.65

New 90-day high: CA$1.23

New 90-day high: CA$1.15

New 90-day low: CA$0.75

Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: CA$0.80

New 90-day low: CA$0.93

New 90-day high - CA$1.26

First half earnings released

Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020

Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven